– USA, MA – TheracosBio today announced the appointment of Jim Greenwood to the Board of Directors of its parent company and Jeff McGroarty as CFO.
“Accomplished leaders, Jim and Jeff will be valuable members of our team at this critical time for TheracosBio. Following FDA approval of BRENZAVVY, we are preparing to develop and execute a commercialization strategy in line with the mission of TheracosBio. I am grateful to have Jim and Jeff on our team and look forward to collaborating with them,” said CEO, Dr. Al Collinson.
About Jim Greenwood
Congressman Jim Greenwood is an established leader in life sciences across business and public policy, and Mr. McGroarty has served as a CFO of public and private life sciences and technology companies. Both newly appointed team members will help shape the commercial strategy for Brenzavvy, a recently FDA-approved treatment for type 2 diabetes.
Congressman Greenwood serves as Chair of the DLA Piper Life Sciences Policy and Advocacy Group, in which capacity he advises clients on a variety of legislative, regulatory, and policy issues impacting the healthcare and life sciences sectors. He represented the Pennsylvania Eighth Congressional District (mostly now the First Congressional District) from 1993 to 2005 and was a leader in healthcare and the environment. From 2005 to 2020 he served as President and CEO of BIO, a trade association that represents 1,000 biotechnology companies, academic institutions, and state biotechnology centers across the US and in more than 30 countries.
About Jeff McGroarty
Jeff McGroarty most recently served as CFO of Annovis Bio (NYSE: ANVS), a biotechnology company focused on neurodegenerative disorders and helped to orchestrate the 2020 IPO of the company. Previously, he spent nearly 13 years in roles of increasing responsibility, culminating in CFO, at Safeguard Scientifics (NYSE: SFE), a capital provider to technology-driven businesses in sectors including healthcare. Mr. McGroarty has also served as VP of Financial Planning and Analysis at Exide Technologies and as a Senior Manager at PricewaterhouseCoopers. He holds an MBA from the Wharton School of the University of Pennsylvania.
“It has been well established that the current US healthcare landscape is not sufficiently aligned with patients’ needs, and I am pleased with the business model of TheracosBio to advance drugs like BRENZAVVY,” said Congressman Jim Greenwood. “BRENZAVVY could expand treatment options for millions of patients with type 2 diabetes in the US, and I am proud to join the Board of Directors ahead of TheracosBio’s first commercial launch.”
TheracosBio develops novel therapeutics for diseases with significant societal impact. The mission of TheracosBio is to expand access to new medications for patients with common diseases.
For more information: https://theracosbio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.